US Patent Issued to Annexon on Sept. 15 for "Method of treating a blood disorder associated with C1q-mediated activation of the classical complement pathway by administering an anti-C1q antibody" (California Inventors)

ALEXANDRIA, Va., Sept. 15 -- United States Patent no. 12,735,473, issued on Sept. 15, was assigned to Annexon Inc. (Brisbane, Calif.).

"Method of treating a blood disorder associated with C1q-mediated activation of the classical complement pathway by administering an anti-C1q antibody" was invented by Ted Yednock (Forest Knolls, Calif.) and Sethu Sankaranarayanan (Fremont, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure relates generally to methods of preventing, reducing risk of developing, or treating a blood disorder (e.g., cold agglutinin hemolytic anemia (cold agglutinin disease), cold antibody hemolytic anemia, ABO incompatible acute hemolytic reactions, warm agglutinin hem...